drugset / Trial / NCT02548962
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Non-randomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma. Phase 2b is a randomized, double-blind, multicenter study of ibrutinib or placebo, in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2016-03
- Primary completion
- 2018-06-13
- Completion
- 2018-06-13
Outcome
Outcome not reported
Stopped: “After completing Phase 1, the Sponsor elected not to move forward with Phase 2.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Pomalidomide | Other / unclassified | — | Oral |